Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.49 |
| ▸ | ACHE | P22303 | 6/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277168 | 1.00 | BCHE (0.49) | BCHEACHEABCG2LMNAHTT | |
| SCHEMBL2281153 | 0.95 | BCHE (0.48) | BCHEACHEABCG2LMNAHTT | |
| SCHEMBL2281156 | 0.95 | BCHE (0.48) | BCHEACHEABCG2LMNAHTT | |
| SCHEMBL2278603 | 0.88 | ABCG2 (0.47) | ABCG2LMNAHTTAPPMAPT | |
| SCHEMBL2278601 | 0.88 | ABCG2 (0.47) | ABCG2LMNAHTTAPPMAPT | |
| SCHEMBL2277070 | 0.85 | ABCG2 (0.45) | BCHEABCG2LMNAHTTAPP | |
| SCHEMBL2277067 | 0.85 | ABCG2 (0.45) | BCHEABCG2LMNAHTTAPP | |
| SCHEMBL2281621 | 0.85 | ABCG2 (0.43) | BCHEACHEABCG2LMNAHTT | |
| SCHEMBL2281615 | 0.85 | ABCG2 (0.43) | BCHEACHEABCG2LMNAHTT | |
| SCHEMBL2281619 | 0.84 | ABCG2 (0.42) | ABCG2LMNAHTTAPPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989478-B2 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7989478-B2 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7989478-B2 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20060211680-A1 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-21 | — | — | US | disclosed |
| EP-1671948-A1 | CINNAMOYL COMPOUND AND USE OF THE SAME | Sumitomo Chemical Company, Limited (JP) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211680-A1 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | COL2A1, COL1A1, COL14A1 | BCHE 4659/4885ACHE 4883/4885ABCG2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.